Clinical Trial Update: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for tivozanib in recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Tivozanib (tivozanib)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-02-28